zoeti spun lead global manufactur medic vaccin
livestock revenu companion anim revenu
result solid despit harsher fx environ livestock headwind
attribut african swine fever china neg impact cattl
relat time distributor purchas companion anim busi
drove outsiz growth oper revenu includ
contribut abaxi continu growth key dermatolog product
well simparica revolut maintain buy rate
divers busi model mitig near-term livestock headwind
 pipelin drive meaning growth next sever year
updat estim rais price target
nutshel adjust ep higher consensu
higher estim revenu increas
in-lin consensu fx neg
bp impact oper growth organ cc
growth driven price volum companion anim
oper revenu growth driven growth
intern growth livestock sale decreas oper
driven declin declin intern gross
margin increas bp vs estim driven
mix-shift higher margin companion anim sale
african swine fever near-term headwind time distributor
purchas neg impact cattl swine product sale
intern livestock oper due headwind
includ lower sale china oper due african
swine fever divestitur certain agribusi product japan
lead cc declin stricter commerci price polici
chang brazil african swine fever continu impact zoeti
near-term manag remain confid livestock sale increas
year optimist compani deliv high-singl digit
oper growth mid-singl digit organ growth
strong companion anim growth drive result highlight
strength busi model estim companion anim revenu
increas oper exclud abaxi contribut
off-set livestock headwind driven increas sale key
dermatolog product apoquel cytopoint oper
 well parasiticid revolut simparica continu
impress zoetiss divers product portfolio optimist
level stabil provid face near-term headwind
page
period except per share revenueadj epsrevenueadj epsrevenueadj epsrevenueadj previou revis compani data factset estim craig-hallum capit group llc
revenu varianc detail
new product drive signific growth organ
oper growth came price came volum
includ key dermatolog product apoquel cytopoint
new product simparica partial off-set
declin in-lin product manag look invest
 pipelin year expect launch proheart
inject parasiticid formul protect dog heartworm
month pend fda approv regulatori review underway
simparica trio eu canada brazil japan china
australia pend regulatori approv expect launch tripl
combo parasiticid think could first market
 area invest includ limit monoclon
antibodi mab therapeut pain dog cat mab
dermatolog cat vaccin livestock life-cycle enhanc
key product remain focus area anim health
includ diagnost devic data analyt digit technolog
oper higher estim
constant currenc basi sale dog cat product increas
equin product sale zoetiss dermatolog
franchis continu drive strong growth sale simparica
apoquel apoquel sale increas oper
consist
intern sale also announc approv apoquel
china larg opportun
cytopoint cytopoint sale increas oper
driven sale
simparica simparica sale total driven
revenu intern market
revenu decreas y/i
oper fx neg impact
higher estim
livestock revenu decreas
lower estim driven
oper growth vs estim fx
bp headwind livestock sale driven
page
varianc varianc except per share c-h estimate con actualto c-h estimate c-h estimate expect revenu driven abaxi contribut strong companion animaly/i partial off-set livestock headwind cattl swine companion oper growth driven strong parasiticid sale primarili revolut cat y/i dog key dermatolog product livestock sale impact time distributor purchas mfa due toy/i partial off-set higher poultri sale driven altern antibiot ernat oper companion oper companion anim sale driven higher sale apoquel cytopoint y/i abaxi primarili oper livestock product sale due african swine fever impact china divestitur certainy/i product japan well chang commerci price polici braziloper oper revenu increas due price growth volum growth keyy/i product sale contribut growth new product ad growthoper compani data factset estim craig-hallum capit group llc
growth poultri fish sheep product
off-set declin cattl swine
companion anim revenu increas y/i
higher estim
driven oper growth vs estim
partial off-set bp fx headwind strong companion
anim growth driven contribut abaxi
increas sale simparica dog stronghold cat
well increas sale apoquel cytopoint
countri perspect oper cc growth strongest
mexico spain experienc
weaker growth japan china brazil
compani data craig-hallum capit group llc estim
zoeti inc page
otherothertot million australiabrazilcanadachinafr germani italyjapanmexicospainuk compani report craig-hallum capit groupquarterli i/ varianceactualc-h estimate variancevari million except per in-lin consensu slightli lower estim due lowerchang sale partial off-set higher growthchang margin expand bp due mix-shift greater sale companion animalgross still expect cost increas next coupl quarter ramp peak parasiticid season project rampamort oper oper oper interest expens guidanc reduc expect tax due season time issu still expect tax yearnet net incom attr incom attribut net incom growth ebitda analysi oper incom attr
revenu categori reflect strong growth companion anim product
simparica revolut parasiticid revenu account
total revenu year ago sale anti-infect medic feed
addit decreas respect
abaxi acquisit propel diagnost revenu account
revenu pharmaceut crept higher sale
revenu speci continu reflect strong growth companion anim
product like apoquel cytopoint simparica revolut driven
dog cat revenu percent revenu year
ago sale cattl product declin cc basi cattl still account
total revenu swine follow poultri
aquacultur product sale increas oper account
total revenu
ep guidanc maintain revenu adjust fx zoeti updat
guidanc harsher fx environ howev full year adjust ep
guidanc still expect rang importantli organ
oper revenu growth still expect year
zoeti inc page
feed man hh guidanceupdatedprevi million except per share fy oper cost sale sg interest expens andoth tax rate adj dilut net signific item andacquisition-rel dilut compani data factset estim chlm estim
increas price target base ev/ebitda multipl
ebitda estim project net debt
share outstand price target also support appli price-to-earnings
multipl ep estim valuat
support long-term discount cash flow dcf valuat analysi use
termin growth rate wacc
believ invest zoeti involv follow risk
increas restrict ban use antibiot use growth promot
livestock fda work phase-out use medic import antibacteri
anim feed growth promot chang produc behavior increas regul
could advers impact zoetiss antibacteri product sale
lead chang underli market demand product
chang util product relat protein consumpt chang
consum spend habit diet protein consumpt could advers effect
zoeti busi
infecti diseas outbreak variou infecti diseas avian flu swine flu
etc could lead cull herd reduct use product
cash pay busi therefor chang economi input cost commod
price could neg impact produc abil buy product
industri consolid increas competit continu consolid
anim health industri could lead increas competit result price pressur
could neg impact margin profit
foreign currenc fluctuat approxim zoeti busi deriv
outsid creat foreign currenc risk
zoeti inc page
page
zoetiscraig-hallum capit groupincom statement mm except per share kevin ellich oper oper oper tax net incom attr non-controlling incom attribut ebitda analysi oper incom attribut non-controlling oper incom attribut compani report craig-hallum capit group llc estimatesmay requir disclosur
